MX2021011788A - Inhibidores de la proteina quinasa c atipica y su uso en el tratamiento de canceres dependientes de la via hedgehog. - Google Patents

Inhibidores de la proteina quinasa c atipica y su uso en el tratamiento de canceres dependientes de la via hedgehog.

Info

Publication number
MX2021011788A
MX2021011788A MX2021011788A MX2021011788A MX2021011788A MX 2021011788 A MX2021011788 A MX 2021011788A MX 2021011788 A MX2021011788 A MX 2021011788A MX 2021011788 A MX2021011788 A MX 2021011788A MX 2021011788 A MX2021011788 A MX 2021011788A
Authority
MX
Mexico
Prior art keywords
hedgehog pathway
inhibitors
protein kinase
dependent cancers
treating
Prior art date
Application number
MX2021011788A
Other languages
English (en)
Inventor
Anthony E Oro
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MX2021011788A publication Critical patent/MX2021011788A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para el tratamiento de cánceres dependientes de la vía hedgehog. Los aspectos de los métodos incluyen la inhibición del crecimiento, la proliferación y/o la metástasis del cáncer dependiente de la vía hedgehog, promovido por la señalización de la vía hedgehog. En particular, se divulgan métodos para tratar los cánceres dependientes de la vía hedgehog con inhibidores de proteína quinasa C atípica iota.
MX2021011788A 2019-03-28 2020-03-27 Inhibidores de la proteina quinasa c atipica y su uso en el tratamiento de canceres dependientes de la via hedgehog. MX2021011788A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825334P 2019-03-28 2019-03-28
PCT/US2020/025437 WO2020198670A1 (en) 2019-03-28 2020-03-27 Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers

Publications (1)

Publication Number Publication Date
MX2021011788A true MX2021011788A (es) 2022-01-24

Family

ID=72611927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011788A MX2021011788A (es) 2019-03-28 2020-03-27 Inhibidores de la proteina quinasa c atipica y su uso en el tratamiento de canceres dependientes de la via hedgehog.

Country Status (12)

Country Link
US (1) US20220143028A1 (es)
EP (1) EP3947380A4 (es)
JP (1) JP2022527320A (es)
KR (1) KR20220002930A (es)
CN (1) CN114206865A (es)
AU (1) AU2020248096A1 (es)
BR (1) BR112021019204A2 (es)
CA (1) CA3135196A1 (es)
IL (1) IL286699A (es)
MX (1) MX2021011788A (es)
SG (1) SG11202110270YA (es)
WO (1) WO2020198670A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073964B2 (en) * 2011-05-06 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
MX2015004016A (es) * 2012-09-28 2016-02-18 Ignyta Inc Inhibidores de azaquinazolina de la proteina quinasa c atipica.
US9192609B2 (en) * 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
EP3665482A4 (en) * 2017-08-11 2021-06-30 Board Of Regents, The University Of Texas System TARGETING KINASES FOR THE TREATMENT OF CARCINOUS METASTASES

Also Published As

Publication number Publication date
JP2022527320A (ja) 2022-06-01
EP3947380A1 (en) 2022-02-09
WO2020198670A1 (en) 2020-10-01
SG11202110270YA (en) 2021-10-28
EP3947380A4 (en) 2023-01-11
AU2020248096A1 (en) 2021-10-14
WO2020198670A9 (en) 2020-11-19
IL286699A (en) 2021-12-01
CA3135196A1 (en) 2020-10-01
CN114206865A (zh) 2022-03-18
BR112021019204A2 (pt) 2021-11-30
US20220143028A1 (en) 2022-05-12
KR20220002930A (ko) 2022-01-07

Similar Documents

Publication Publication Date Title
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
PH12017501155B1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
PH12019502602A1 (en) Polypeptides antagonizing wnt signaling in tumor cells
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
AU2015314007B2 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
IL280158A (en) Methods of treating cancer with the PI3K inhibitor, GDC-0077
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
MX2022004766A (es) Terapias combinadas con venetoclax e inhibidores de tim-3.
ZA202108579B (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
MX2020006297A (es) Variantes de cd19.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2021006326A (es) Inhibidores de pcna.
MX2022004769A (es) Inhibidores de tim-3 y sus usos.
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
EP3758678A4 (en) CANCER TREATMENT METHODS INCLUDING CHK1 INHIBITORS
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
WO2018102766A9 (en) Small molecule bcl-2 functional converters as cancer therapeutics